Effect of periaqueductal gray melanocortin 4 receptor in pain facilitation and glial activation in rat model of chronic constriction injury

Neurological Research

Volumn 34, Issue 9, 2012, Pages 871-888

  Chu, Haichen ^a   Sun, Junzhi ^b   Xu, Hongmei ^a   Niu, Zejun ^a   Xu, Mei ^c  

^a QINGDAO UNIVERSITY   (China)

^b AFFILIATED HOSPITAL OF INNER MONGOLIA MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Astrocytes; Cytokines; HS014; Microglia; Neuropathic pain

Indexed keywords

AGOUTI RELATED PROTEIN; BETA INTERMEDIN[11-22][11 (N ACETYLCYSTEINE) 14 [3 (2 NAPHTHYL) DEXTRO ALANINE] 18 CYSTEINE 22 ASPARTIC ACID AMIDE] 11,18 CYCLIC DISULFIDE; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MELANOCORTIN 4 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ALLODYNIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC CONSTRICTION INJURY; EXPERIMENTAL MODEL; GLIA; GLIA CELL; HYPERALGESIA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NONHUMAN; PAIN; PERIAQUEDUCTAL GRAY MATTER; PERIPHERAL NERVE INJURY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGOUTI-RELATED PROTEIN; ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS, CD11B; CONSTRICTION; CYTOKINES; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; HYPERALGESIA; MALE; MICROINJECTIONS; NEUROGLIA; PAIN MEASUREMENT; PAIN THRESHOLD; PEPTIDES, CYCLIC; PERIAQUEDUCTAL GRAY; PRO-OPIOMELANOCORTIN; RATS; RATS, WISTAR; RECEPTOR, MELANOCORTIN, TYPE 4; SCIATICA; TIME FACTORS;

EID: 84867916990     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1179/1743132812Y.0000000085     Document Type: Article

References (53)

1. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science. 2000;288:1765-1769.
2. Gebhart GF. Descending modulation of pain. Neurosci Biobehav Rev. 2004;27:729-737.
3. Gardell LR, Vanderah TW, Gardell SE, Wang R, Ossipov MH, Lai J, et al. Enhanced evoked excitatory transmitter release in experimental neuropathy requires descending facilitation. J Neurosci. 2003;23:8370-8379.
4. Fu KY, Light AR, Matsushima GK, Maixner W. Microglial reactions after subcutaneous formalin injection into the rat hind paw. Brain Res. 1999;825:59-67.
5. Fu KY, Light AR, Maixner W. Relationship between nociceptor activity, peripheral edema, spinal microglial activation and long-term hyperalgesia induced by formalin. Neuroscience. 2000;101:1127-1135.
6. Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological pain. Trends Neurosci. 2001;24:450-455.
7. Watkins LR, Maier SF. Glia: a novel drug discovery target for clinical pain. Nat Rev Drug Discov. 2003;2:973-985.
8. Meller ST, Dykstra C, Grzybycki D, Murphy S, Gebhart CF. The possible role of glia in nociceptive processing and hyperalgesia in the spinal cord of the rat. Neuropharmacology. 1994;33:1471-1478.
9. Ridet JL, Malhotra SK, Privat A, Gage FH. Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci. 1997;20:570-577.
10. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996;19:312-318.
11. Milligan ED, Twining C, Chacur M, Biedenkapp J, O'Connor K, Poole S, et al. Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J Neurosci. 2003;23:1026-1040.
12. Raghavendra V, Tanga F, DeLeo JA. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J Pharmacol Exp Ther. 2003;306:624-630.
13. Sweitzer S, Martin D, DeLeo JA. Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain. Neuroscience. 2001;103:529-539.
14. McMahon SB, Cafferty WB, Marchand F. Immune and glial cell factors as pain mediators and modulators. Exp Neurol. 2005;192:444-462.
15. Deleo JA, Tanga FY, Tawfik VL. Neuroimmune activation and neuroinflammation in chronic pain and opioid tolerance/ hyperalgesia. Neuroscientist. 2004;10:40-52.
16. Raghavendra V, Tanga FY, DeLeo JA. Complete Freunds adjuvant-induced peripheral inflammation evokes glial activation and proinflammatory cytokine expression in the CNS. Eur J Neurosci. 2004;20:467-473.
17. Zhao P, Waxman SG, Hains BC. Modulation of thalamic nociceptive processing after spinal cord injury through remote activation of thalamic microglia by cysteine chemokine ligand 21. J Neurosci. 2007;27:8893-8902.
18. Roberts J, Ossipov MH, Frank P. Glial activation in the rostroventromedial medulla promotes descending facilitation to mediate inflammatory hypersensitivity. Eur J Neurosci. 2009;30:229-241.
19. Wei F, Guo W, Zou S, Ren K, Dubner R. Supraspinal glial- neuronal interactions contribute to descending pain facilitation. J Neurosci. 2008;28:10482-10495.
20. Bertolini A, Poggioli R, Ferrari W. ACTH-induced hyperalgesia in rats. Experientia (Basel). 1978;35:1216-1217.
21. Sandman CA, Kastin AJ. Intraventricular administration of MSH induces hyperalgesia in rats. Peptides. 1981;2:231-233.
22. Williams DW, Lipton JM, Giesecke AH. Influence of centrally administered peptides on ear withdrawal in the rabbit. Peptides. 1986;7:1095-1100.
23. Bellasio S, Nicolussi E, Bertorelli R, Reggiani A. Melanocortin receptor agonists and antagonists modulate nociceptive sensitivity in the mouse formalin test. Pharmacology. 2003;482(1-3):127-132.
24. Starowicz K, Przewlocki R, Gispen WH, Przewlocka B. Modulation of melanocortin-induced changes in spinal nociception by m-opioid receptor agonist and antagonist in neuropathic rats. Neuroreport. 2002;13:2447-452.
25. Vrinten DH, Gispen WH, Groen GJ, Adan RA. Antagonism of the melanocortin system reduces cold and mechanical allodynia in mononeuropathic rats. J Neurosci. 2000;20(21):8131-8137.
26. Beltramo M, Campanella M, Tarozzo G, Fredduzzi S, Corradini L, Forlani A, et al. Gene expressionprofiling of melanocortin system in neuropathic rats supports a role in nociception. Brain Res Mol Brain Res. 2003;118(1-2):111-18.
27. Bertorelli R, Fredduzzi S, Tarozzo G, Campanella M, Grundy R, Beltramo M, et al. Endogenous and exogenous melanocortin antagonists induce anti-allodynic effects in a model of rat neuropathic pain. Behav Brain Res. 2005;157:55-62.
28. Starowicz K, Mousa SA, Obara I, Chocyk A, Przewłocki R, Wedzony K, et al. Peripheral antinociceptive effects of MC4receptor antagonists in a rat model of neuropathic pain - a biochemical and behavioral study. Pharmacol Rep.2009;61:1086-1095.
29. Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain. 1988;33:87-107.
30. Paxinos G, Watson C. The rat brain in stereotaxic coordinates, 5th ed. Amsterdam: Elsevier Academic Press; 2005.
31. Sun S, Cao H, Han M, Li TT, Pan HL, Zhao ZQ, et al. New evidence for the involvement of spinal fractalkine receptor in pain facilitation and spinal glial activation in rat model of monoarthritis. Pain. 2007;129(1-2):64-75.
32. Chu HC, Xia JL, Yang Z, Gao J. Melanocortin 4 receptor induces hyperalgesia and allodynia after chronic constrictioninjury by activation of p38MAPK in DRG. Int J Neurosci. 2012;122:74-81.
33. Zvejniece L, Muceniece R, Krigere L, Dambrova M, Klusa VZ. The differential influences of melanocortinson nociception in the formalin and tail flick tests. Pharmacol Biochem Behav. 2006;85:287-291.
34. Kalange AS, Kokare DM, Singru PS, Upadhya MA, Chopde CT, Subhedar NK. 2007 Central administration of selectivemelanocortin 4 receptor antagonist HS014 prevents morphine tolerance and withdrawal hyperalgesia. Brain Res. 2007;1181:10-20.
35. Basbaum AI, Fields HL. Endogenous pain control system: rainstem spinal pathway and endorphin circuity. Annu Rev Neurosci. 1987;7:309-338.
36. Saade NE, Jabbur SJ. Nociceptive behavior in animal models for peripheral neuropathy: spinal and supraspinal mechanisms. Prog Neurobiol. 2008;86:22-47.
37. Bertolini A, Tacchi R, Vergoni AV. Brain effects of melanocortins. Pharmacol Res. 2009;59(1):13-47.
38. Wang W, Wang Y, Huang J, Wu S, Li YQ. Temporal changes of astrocyte activation and glutamate transporter-1 expression in the spinal cord after spinal nerve ligation-induced neuropathic pain. Anat Rec (Hoboken). 2008;291:513-581.
39. Mor D, Bembrick AL, Austin PJ, Wyllie PM, Creber NJ Denyer GS. Anatonically specific patterns of glial activation in the periaqueductal gray of the sub-population of rats showingpain and disability following chronic constriction injury of the sciatic nerve. Neuroscience. 2010;166:1167-184.
40. Selkirk JV, Nottebaum LM, Lee J, Yang W. Identification of differential melanocortin 4 receptor agonist profiles at natively expressed receptors in rat cortical astrocytes and ecombinantly expressed receptors in human embryonickidney cells. Neuropharmacology. 2007;52:459-466.
41. Caruso C, Durand D, Schioth HB, Rey R, Seilicovich A, Lasaga M. Activation of melanocortin 4 receptors reduces the inflammatory response and prevents apoptosis induced by lipopolysaccharide and interferon-gamma inastrocytes. Endocrinology. 2007;148:4918-4926.
42. Lindberg C, Hjorth E, Post C, Winblad B, Schultzberg M. Cytokine production by a human microglial cell line: effects of beta-amyloid and alpha-melanocyte stimulating. Neurotox Res. 2005;8(3/4):267-276.
43. Sung B, Lim G, Mao J. Altered expression and uptake activity of spinal glutamate transporters after nerve injury contribute to the pathogenesis of neuropathic pain in rats. J Neurosci. 2003;23:2899-2910.
44. Caruso C, Mohn C, Karara AL, Rettori V, Watanobe H, Schiöth HB, et al. Alpha-melanocyte-stimulating hormone through melanocortin-4 receptor inhibits nitric oxide synthase and cyclooxygenase expression in the hypothalamus of male rats. Neuroendocrinology. 2004;79:278-286.
45. Catania A, Gatti S, Colombo G, Lipton JM. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev. 2004;56:1-29.
46. Colburn RW, Deleo JA, Rickman AJ, Yeager MP, Kwon P, Hickey WF. Dissociation of microglial activation and neuropathic pain behaviors following peripheral nerve injury in the rat. J Neuroimmunol. 1997;79:163-175.
47. Winkelstein BA, DeLeo JA. Nerve root injury severity differentially modulates spinal glial activation in a rat lumbar radiculopathymodel: considerations for persistent pain. Brain Res. 2002;956:294-301.
48. lvaro JD, Tatro JB, Quillan JM, Fogliano M, Eisenhard M, Lerner MR, et al. Morphine down-regulates melanocortin-4 receptor expression in brain regions that mediate opiate addiction. Mol Pharmacol. 1996;50:583-591.
49. Ercil NE, Galici R, Kestorson RA. HS014, a selective melanocortin-4 (MC-4) receptor antagonist, modulates the behavioral effects of morphine in mice. Psychopharmacology.2005;180:279-285.
50. Moskowitz AS, Goodman RR. Autoradiographic distribution of mu1 and mu2 opioid binding in the mouse central nervous system. Brain Res. 1985;360:117-129.
51. Alvaro JD, Tatro JB, Duman RS. Melanocortins and opiate addiction. Life Sci. 1997;6:1-9.
52. Abdel-Malek ZA. Melanocortin receptors: their functions and regulation by physiological agonists and antagonists. Cell Mol Life Sci. 2001;58:434-441.
53. Starowicz K, Sieja A, Bilecki W, Obara I, Przewlocka B. The effect of morphine on MC4 and CRF receptor mRNAs in the rat amygdala and attenuation of tolerance after their blockade. Brain Res. 2003;990:113-119.